加减消风散联合依巴斯汀治疗风热型荨麻疹疗效观察

目的 观察消风散加减方联合依巴斯汀治疗风热型荨麻疹的临床疗效。 方法 将63例风热型荨麻疹患者按随机数字表法随机分为治疗组（n=32）和对照组（n=31），对照组患者口服依巴斯汀，治疗组口服依巴斯汀和消风散加减方，疗程2周。治疗前、治疗7 d末、治疗14 d末，分别观察两组患者荨麻疹活动度评分（urticaria activity score，UAS）和皮肤病生活质量指数（the dermatology life quality index，DLQI），治疗7 d和14 d末，分别观察两组临床疗效。 结果 治疗前和治疗7 d末，两组UAS及DLQI比较，差异均无统计学意义（P>0.05）；治疗14 d末，两组UAS和DLQI比较，差异具有统计学意义（P<0.05）。治疗7 d末和14 d末，两组UAS和DLQI均较前一时点显著降低（P<0.05）。治疗14 d末，两组临床疗效比较，差异具有统计学意义（P<0.05），治疗组临床疗效优于对照组。两组荨麻疹痊愈时间以及复发率比较，差异均无统计学意义（P>0.05）。 结论 消风散加减方联合依巴斯汀治疗急性荨麻疹疗效确切，其长期疗效优于单用依巴斯汀。

Clinical Efficacy of Modified Xiaofeng Powder Combined with Ebastine Tablets for Urticaria of Wind heat Type

Objective To observe the clinical efficacy of modified Xiaofeng Powder combined with ebastine tablets for urticaria of wind-heat type. Methods Sixty-three patients with urticaria of wind-heat type were randomly divided into treatment group (n=32) and control group (n=31) according to the random number table. Patients in the control group were given ebastine tablets for two weeks, while patients in the treatment group were given ebastine tablets combined with modified Xiaofeng Powder for two weeks. The urticaria activity score (UAS) and dermatology life quality index (DLQI) were evaluated in the two groups before and after 7 and 14 days of treatment. The clinical outcomes in the two groups were evaluated after 7 and 14 days of treatment. Results There were no significant differences in UAS and DLQI scores between the two groups before and after 7 days of treatment (P>0.05). However, there were significant differences in UAS and DLQI scores between the two groups after 14 days of treatment (P<0.05). In the two groups, the UAS and DLQI scores after 7 and 14 days of treatment were significantly higher than those at the previous time points (P<0.05). After 14 days of treatment, the treatment group had significantly better clinical outcomes than the control group (P<0.05). However, there were no significant differences in time to recovery and recurrence rate of urticaria between the two groups (P>0.05). Conclusion Modified Xiaofeng Powder combined with ebastine tablets has definitive efficacy in the treatment of acute urticaria, which achieves superior long-term efficacy over ebastine tablets alone.